Bluewater Health is taking part in a nationwide COVID-19 treatment study.
The 40-hospital study is using blood plasma taken from people who have recovered from the virus and testing its safety and effectiveness as a treatment for others, the hospital said.
The study will help determine whether recovered patients developed the antibodies needed to help hospitalized patients avoid serious illness or death.
Participants in the trial must be 16 or older, require oxygen, have been sick less than 12 days, and have plasma compatible with the donor, the hospital said.
The physician providing hospital care and the research team will determine a patient’s eligibility.
About 350 people in Sarnia-Lambton have recovered from the virus and 25 have died.
“Participating in a study of this calibre is a testament to our local skill set,” said Dr. Mike Haddad, the hospital’s chief of staff.
“We hope that our contribution, along with the other centres, would illuminate any potential benefit of this therapy in hospitalized COVID-19 patients.”